A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.
about
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaPopulation Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human studyApplication of quantitative pharmacology in development of therapeutic monoclonal antibodiesPharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeysPharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.Long-term benefits of omalizumab in a patient with severe non-allergic asthmaOmalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects.Applications of minimal physiologically-based pharmacokinetic models.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibodyPopulation pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapyFactors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.An IgE receptor mimetic peptide (PepE) protects mice from IgE mediated anaphylaxis.Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics.Therapeutic monoclonal antibody concentration monitoring: free or total?Monoclonal antibodies for the treatment of severe asthma.PK-PD modeling of protein drugs: implications in assay development.A guide to rational dosing of monoclonal antibodies.Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation.Comparable actions of omalizumab on mast cells and basophils.AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.
P2860
Q27689386-FF3B4C6C-BBED-4202-9B3B-142C3F65FA7DQ33581536-E9A36B4F-0328-4EF8-802B-D870B9C126BDQ34187345-3900767B-A66E-431E-A993-21F8888119F6Q34293689-3554D2B9-3240-458C-930C-9F6996F1A77AQ34293733-AAC7D408-3EE5-4E06-9FE9-9437A1C36495Q34782224-1AC7AE16-9BC9-4526-8029-00DBB5B8D953Q34805259-B093830F-12F4-41AA-9F1C-B6CC0F6DEE2BQ34901024-686A399A-EFC7-4A4D-A28A-0EA1F5BBD089Q35023731-2463E00A-EF6C-48D8-8872-35A34389A7C7Q35078215-2C07ABFF-BD79-4189-B2A6-D7C90F73E91AQ35183644-41F59AC7-B027-465A-968D-78930677F5A4Q35640448-F2C2DC76-FB2A-4F5C-9E33-E159195CE537Q35879455-3E448AA3-F9D8-4A41-A34A-60BAAFEBC7FCQ35918874-F9078B5A-E4B2-4E7B-B944-7301868EAFF1Q36517093-26C22762-D3A9-454B-BD71-ACF620FDE5A6Q36579912-F4C8A9E5-D29B-4887-AF7F-A2BAAE5A2A0BQ36644667-C2CB94EA-88EB-4BF5-A56E-2118D2D8DC3CQ36706795-7A5E7A09-F444-4783-AC67-868BB9C84089Q36806664-69A6AEDA-2C46-4055-AD2D-4A9D7BFEE87BQ36910587-907A1A4D-FFD0-4429-8081-0D00186C0A33Q36951905-9E11180A-BAC6-4AE2-B67D-3D1CA612252BQ37161497-53B87ECF-3EC0-45FF-9033-FA8199F9518FQ37288228-5ED5FACA-869F-4868-BE96-395006CC9710Q37510861-DC869916-0578-40E3-8244-9B6F6BD82F0CQ37635011-2F730CC3-2685-48E7-8C8F-F7B5597FCE3DQ37810157-F8474356-268B-423E-B961-D8B2BD8CE3EAQ37810218-2E89CBBB-6829-4B2E-9D7C-4F34A428292DQ37848219-D736F0F9-7691-44A0-BE1B-820B26781E2BQ37854638-E3BA40F3-31C8-4C6A-9DC7-C47BB5BE5263Q37976878-0DA74784-489F-44A2-AB89-2410984B8D2DQ38060204-70F25ACD-4A43-474A-85DA-B40A8B1405FAQ38072598-D5F9ACAA-D083-4F11-A91E-35E5A69F018BQ38364466-9F308EF4-6FC7-48C5-B646-2A3D6A2EB8B0Q38396322-9159F5C6-D37C-4F14-A45F-BBC907AB41E6Q38504671-6B47E9D3-5580-4838-98D7-883172CA9D60Q38540353-325F8E56-3640-4A8A-957D-D13416E29C4DQ38714339-6AFA8FDD-E2F0-49A6-9D81-8B3B836A1A62Q38728589-3E02B28C-A297-4010-A2CF-F3344EC09797Q38824255-11153575-7D88-4CCE-A0EA-2DB5C2E8FE53Q38856152-5590EDD6-79A4-40EE-9949-FCDCA54140B6
P2860
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A mechanism-based binding mode ...... harmacodynamics of omalizumab.
@en
type
label
A mechanism-based binding mode ...... harmacodynamics of omalizumab.
@en
prefLabel
A mechanism-based binding mode ...... harmacodynamics of omalizumab.
@en
P2860
P1476
A mechanism-based binding mode ...... pharmacodynamics of omalizumab
@en
P2093
William M Sallas
Yuko Tsukamoto
P2860
P304
P356
10.1111/J.1365-2125.2006.02803.X
P407
P577
2006-11-10T00:00:00Z